EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts

Cristina Rebordosa iD, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15429 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Cristina Rebordosa und 11 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Barcelona, Spain. Hauptthemen laut MEDLINE: Acute Kidney Injury, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To estimate risks of diabetic ketoacidosis (DKA), acute liver injury (ALI), acute kidney injury (AKI), chronic kidney disease (CKD), severe complications of urinary tract infection (UTI) and genital infection (GI) among patients with type 2 diabetes initiating empagliflozin versus those initiating a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. Materials and Methods In this large multinational, observational, new‐user cohort study in UK, Danish and US healthcare data sources, patients initiated empagliflozin or a DPP‐4 inhibitor between August 2014 and August 2019, were aged ≥18 years, and had ≥12 months' continuous health plan enrolment. Incidence rates by exposure and incidence rate ratios, adjusted for propensity‐score deciles, were calculated.

Results

In total, 64 599 empagliflozin initiators and 203 315 DPP‐4 inhibitor initiators were included. There was an increased risk [pooled adjusted incidence rate ratios (95% confidence interval)] of DKA [2.19 (1.74‐2.76)] and decreased risks of ALI [0.77 (0.50‐1.19) in patients without predisposing conditions of liver disease; 0.70 (0.56‐0.88) in all patients] and AKI [0.54 (0.41‐0.73)]. In the UK data, there was an increased risk of GI [males: 4.04 (3.46‐4.71); females: 3.24 (2.81‐3.74)] and decreased risks of CKD [0.53 (0.43‐0.65)] and severe complications of UTI [0.51 (0.37‐0.72)]. The results were generally consistent in subgroup and sensitivity analyses.

Conclusions

Compared with DDP‐4 inhibitor use, empagliflozin use was associated with increased risks of DKA and GI and decreased risks of ALI, AKI, CKD and severe complications of UTI. These associations are consistent with previous studies and known class effects of sodium‐glucose cotransporter 2 inhibitors, including renoprotective effects and beneficial effects on alanine aminotransferase levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryBenzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic KetoacidosisDipeptidyl-Peptidase IV InhibitorsGlucosidesRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsUrinary Tract InfectionsAdolescentAdultFemaleHumansMaleCohort StudiesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHypoglycemic AgentsLiver

Stichwörter der Autor:innen

antidiabetic drugempagliflozinpharmacoepidemiologyreal-world evidence

Substanzen

Benzhydryl CompoundsDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesempagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • RTI Health Solutions, Barcelona, Spain.
  • Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
  • Carelon Research, Wilmington, Delaware, USA.
  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA.

ORCID-Profile: Cristina Rebordosa

Förderung

  • Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Zitieren

APA

Rebordosa, C., Thomsen, R. W., Tave, A. K., Madsen, M., Beachler, D. C., Martinez, D., Garcia-Esteban, R., Plana, E., Tormos, A., Farsani, S. F., Perez-Gutthann, S., & Pladevall-Vila, M. (2024). Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15429

Vancouver

Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, et al. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15429

BibTeX
@article{Rebordosa2024,
  author = {Rebordosa, Cristina and Thomsen, Reimar W and Tave, Arlene K and Madsen, Morten and Beachler, Daniel C and Martinez, David and Garcia-Esteban, Raquel and Plana, Estel and Tormos, Anita and Farsani, Soulmaz Fazeli and Perez-Gutthann, Susana and Pladevall-Vila, Manel},
  title = {Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15429}
}
Kostenlos starten →